Home › Forums › Clinical Practice › prescribing GLP-1s in psychiatry › Reply To: prescribing GLP-1s in psychiatry
March 21, 2025 at 12:34 pm
#1344
Hi all–
I’m a psychiatrist and continue to be involved in a limited way with resident teaching. A few things that I can add:
- Psychiatrists are just as susceptible to weight bias as any other specialty. One piece that is worth considering that hasn’t been mentioned yet is that we are also frequently trained in motivational interviewing (namely for substance use disorders), although this can also get conflated with “lifestyle medicine” and thus be used to push interventions around weight loss/dieting. I’ve also seen a surge of psychiatrists getting boarded in “o****** medicine.”
- Every psychiatrist should be screening for eating disorders at first appointment, though again I don’t think that there is enough recognition around the prevalence of eating disorders across all body sizes. One would posit that though EDs are being screened for, some may be screened out due to provider bias. Finally, some institutions are very “siloed” — a psychiatrist who mainly treats psychosis and thus is more likely to prescribe an SGA may only very rarely treat EDs.
- Re: SGAs — this is a trickier discussion. Of course these medications are associated with weight gain. Psychiatrists (outside of en emergent setting) are generally good about counseling about the risk of weight gain, DM2, HLD. Patients should also been screened for DM2 via HbA1c and HLD via lipid panel yearly while on an SGA. I order this on my own if pt does not have a PCP. I know many psychiatrists will start metformin for patients, but do not hear psychiatrists routinely starting insulin, statins, etc.
- An interesting piece to consider here is that SGAs were pivoted to because first generation antipsychotics are more often a/w TD and SGAs are also thought to better treat negative symptoms due to their different mechanism of action. There is something really icky (scientific term) about this to me because there are rumblings of discussion that perhaps we should turn more back towards meds with a higher risk of TD so “at least they won’t be gaining weight.” As if the stigma of having TD and being in a larger body are somehow on the same level.
- I have increasingly seen posts on psychiatrist FB groups that I am a member of about starting GLP1s for weight gain 2/2 medications. They’re typically loaded with weight stigma and plenty of posts around how they have helped the psychiatrist themselves feel more confident, etc. There is a mix of what seems to be ill informed, but good intentions which point out that our patients are exposed to more stigma than the average joe at baseline and this is one way to “help” with that.
- I personally have come up against a brick wall when pointing to an increased risk of SI as outlined in Wegovy’s package insert as well as the fact that patients with SPMI are excluded from these studies. The response I typically get when pointing out the latter is “of course they didn’t include SPMI and they never will.”
- On a practical level, I find it to be a pretty tough sell for many of my patients to consider LAIAs. I wonder how they plan to get a population on board with taking weekly injections when it’s so hard to get them into clinic q3-4wks for LAIAs.
- Regarding the initial post’s question about how to broach this with a training program: I think there could be a really valuable opening here for a discussion around countertransference in the dr/pt relationship. What is driving a specific psychiatrist to consider this as an intervention that is appropriate for us to provide? How might the psychiatrist imagine feeling if this was brought up to them in this setting if they were the patient?
I appreciate you bringing up this important topic of discussion, I’ve been wondering about it too.